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Abstract
Background: We retrospectively reviewed data from nine pre-treated metastatic desmoplastic small round cell
tumour (DSRCT) patients who received pazopanib.
Patients and methods: Three patients received pazopanib within the EORTC phase II 62043, three in the EORTC
phase III 62072, and three in the context of UK named patient program.
Results: Nine patients were retrieved from the databases, the median age was 30 years (range: 21–47), they were
all males. All had received prior chemotherapy. At the time of treatment start, 4 patients (44%) had ECOG PS 0, 4
(44%) PS 1, 1 (11%) PS 2. Best response was partial response (PR) in 2/9 (22%) patients, stable disease (SD) in 5/9
(56%) and progressive disease (PD) in 2/9 (22%) with a clinical benefit rate (PR + SD > 12 weeks) of 78%. Median
PFS and OS were 9.2 (95%CI: 0–23.2) and 15.4 (95%CI: 1.5-29.3) months respectively. With a median follow-up of
20 months, 2/9 (22%) patients are still alive, all progressed. The most common toxicities included neutropenia (G1-2
45%; G3-4 11%), anaemia (G1-2 45%), fatigue (G1-2 67%), diarrhoea (G1-2 45%; G3-4 11%), nausea (G1-2 45%),
hypertension (G1-2 45%) and increase in liver enzymes (G1-2 34%; G3-4 11%). Three patients (34%) required a dose
reduction. One of the patients discontinued treatment because of persistent increase in total bilirubin level, one due to
patient’s choice.
Conclusion: In this series, pazopanib showed interesting activity in DSRCT patients who progressed after prior
chemotherapy without major toxicity.
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Background
Pazopanib (GW786034) is an orally available inhibitor of
the tyrosine kinases of several factors including the vas-
cular endothelial growth factor receptors (VEGFR) 1–3,
c-KIT, and the platelet-derived growth factor receptors
(PDGFR) alpha and beta [1]. In addition to advanced clear
cell renal cell carcinoma, for which pazopanib received
EMA and FDA approval in 2009 [2], pazopanib has been
assessed in various other tumor types, including soft tissue
sarcoma (STS). Preclinical studies showed that VEGF is
over-expressed and that circulating angiogenic factor
levels correlate with extent of disease and risk of recur-
rence in patients with STS [3,4]. Pazopanib activity in STS
was initially explored in an EORTC single arm phase II
study in patients who failed doxorubicin- and/or
ifosfamide-based chemotherapy, stratified by histology
(adipocytic STS versus leiomyosarcoma versus synovial
sarcoma versus other eligible STS subtypes). In general
pazopanib was well tolerated, with hypertension, fatigue,
hypopigmentation, and nausea being the most common
drug related toxicities, mostly grades (G) 1 to 2. The
progression-free survival rate (PFR) at 12 weeks, was
44% for leiomyosarcoma, 49% for synovial sarcoma and
39% for other types of sarcoma. The low PFR for the
adipocytic sarcoma stratum (26%) led to the exclusion
of this subtype in the subsequent randomised phase III
study (PALETTE) [5]. In the PALETTE study 369 pa-
tients were randomized to receive pazopanib 800 mg/
day versus placebo. Median PFS was 4.6 months (95%CI
3.7–4.8) for pazopanib compared with 1.6 months
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(95%CI 0.9–1.8) for placebo (P < 0.0001). A positive
trend favouring pazopanib was also recorded in overall
survival (12.5 months versus 10.7 months), without
reaching a statistical significance (P = 0.25) [6]. Patients
who had the best chance to benefit with a long survival
were those with a good performance status, low or
intermediate tumor grade and a normal haemoglobin
level at baseline [7]. No differences were recorded ac-
cording to histology (P = 0.61). Consistently with the
data from the phase II study, the most common adverse
events were fatigue, diarrhoea, nausea, weight loss and
hypertension. Overall, the results of the PALETTE study
showed both good tolerability and activity of pazopanib,
supporting its value as a new treatment option in ad-
vanced non-adipocytic STS patients.
Desmoplastic small round cell tumour (DSRCT) is an
unusual subtype of STS, with annual incidence rate of
0.1 case per 1.000.000 [8]. It has distinctive histologic,
genetic and clinical features. DSRCT is considered to be
a member of the family of small blue round cell tumors
and is characterised by a prominent desmoplastic stroma
composed of fibroblasts or myofibroblasts embedded in
a loose extracellular material; stromal vascularity is also well
represented [9]. In 96-97% of all cases, DSRCT harbour
a t(11;22) translocation, which involves a fusion of the
EWSR1 gene, on chromosome 22, with the WT1 gene,
on chromosome 11 [10]. Usually, DSRCT affects young
Caucasian males at adolescent and young adult age and
typically presents with a widespread involvement of the
peritoneal cavity. Crampy abdominal pain and associ-
ated palpable abdominal masses are the most common
signs at presentation, but abdominal fullness, nausea,
constipation and ascites can also be present [11].
Complete surgical resection is the only curative mo-
dality, but usually the disease presents late at a stage
where complete resection is impossible. Alkylator-based
regimens have been proven to be effective in advanced
DSRCT, but durable responses are rare [12]. Other novel
approaches, such as complete cytoreduction and HIPEC
(hyperthermic intraperitoneal chemotherapy) or whole
abdominopelvic intensity-modulated radiation therapy
(WAP-IMRT) combined with chemotherapy, have also
been tested with some promising results [13,14]. However,
the value of these observations is limited due to the small
sample size and the retrospective nature of the studies.
Despite a multimodal approach, the expected 5 years over-
all survival for DSRCT is only 15% [15].
Preclinical studies have shown that VEGFR-2 and
VEGFA are over-expressed in DSRCT and that DSRCT
xenografts can be highly responsive to anti-VEGF agents
such as bevacizumab [16]. One ongoing pivotal trial is
currently assessing the impact of the addition of bevaci-
zumab to a first-line dose dense chemotherapeutic regi-
men [17]. Moreover, EWSR1/WT1 has been proven to
induce the upregulation of PDGF ligand and receptor,
which might be responsible for the prominent tumor-
associated desmoplasia detected in this disease [18-20].
On this bases, imatinib activity was tested in two phase
II studies, showing unfortunately no efficacy in ad-
vanced DSRCT (no response reported) [21,22]. Italiano
et al. recently reported on their experience in advanced
DSRCT patients treated with sunitinib, a multi-kinase
inhibitor that blocks several tyrosine kinase receptors
such as VEGF receptors, PDGF receptors, KIT, FLT3,
and CSF-1. Among eight patients treated, two patients
achieved a partial response (25%), three (37.5%) had stable
disease, and three (37.5%) had progressive disease. Median
progression free survival (PFS) was 2.6 months (95%CI
0–9). Interestingly, one patient was still on treatment
10 months after its initiation [23]. These results suggest
that both VEGFR and PDGFR can represent promising
targets and that small molecule tyrosine kinase inhibitors
(TKIs) blocking these receptors and their downstream
pathways might represent a possible treatment option for
advanced DSRCT patients. Of note, a recent phase I phar-
macokinetic and pharmacodynamic study of pazopanib in
children affected by advanced STS or other refractory
solid tumors reported a sustained partial response (PR) in
a DSRCT patient [24].
Here we describe, for the first time, the activity of
pazopanib in nine pre-treated patients with metastatic
desmoplastic DSRCT, with the aim of reporting on effi-
cacy and tolerability.
Methods
Patients population
We retrospectively reviewed data from nine patients af-
fected by advanced DSRCT progressing on or after prior
chemotherapy, comprising three DSRCT patients treated
within the EORTC phase II study 62043, three in the
EORTC phase III study 62072 (PALETTE), along with
three patients treated in the UK on the subsequent pazo-
panib named patient program (at Royal Marsden Hos-
pital, London, and NHS Lothians, Edinburgh). All cases
were reviewed by sarcoma expert pathologists, familiar
with the diagnosis of DSRCT.
Data collection
Details on patient (age at diagnosis, gender, baseline
ECOG performance status), disease (primary origin,
metastatic sites), treatment (starting dose, dose reduc-
tion, toxicities) and outcome (best response according
to RECIST 1.0 criteria, progression-free survival and
overall survival) were recorded [25]. In the UK data
were extracted and analysed from individual patient
files, the data from patients in the phase 2 and 3 study
were retrieved from the EORTC database in Brussels.
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Statistical analysis
Descriptive analysis was made using median values and
range. Progression-free survival (PFS) and overall sur-
vival (OS) were estimated with Kaplan-Meier method
[26]. PFS was defined as the moment from start of pazo-
panib until progressive disease according to RECIST, or
death. OS was defined as the time from start of pazopa-
nib to death due to any cause. Alive patients were cen-
sored at the time of the last contact. SPSS software
(version 17.00, SPSS, Chicago, ILQ5) was used for statis-
tical analysis. A P value of less than 0.05 was considered
to indicate statistical significance.
Results
Data from nine patients included in this analysis re-
vealed a median age of 30 years (range: 21–47). All pa-
tients were males and were affected by widespread
metastatic DSRCT. Four patients had one previous
chemotherapy line (44%), four had 2 previous chemo-
therapy lines (44%) and one patient 3 (12%). At the time
of treatment start, four patients (44%) had ECOG PS 0,
four (44%) PS 1 and one (11%) PS 2. Pazopanib was
started at 800 mg/day in 8/9 patients (89%) while one
patient received 600 mg/day due to impaired PS. All pa-
tients were evaluable for response. Using RECIST 1.0
criteria, best response was partial response (PR) in 2/9
(22%) patients, stable disease (SD) in 5/9 patients (56%)
and progressive disease (PD) in 2/9 (22%) with a clinical
benefit rate (PR + SD > 12 weeks) of 78%. These data are
summarised in Table 1. Median PFS and OS were 9.2
(95%CI: 0–23.2) and 15.4 (95%CI: 1.5-29.3) months re-
spectively. With a median follow-up of 20 months, 2/9
(22%) patients are still alive, all progressed. The most
common haematological toxicities were neutropenia
(G1-2 45%; G3-4 11%) and anaemia (G1-2 45%), while
non-haematological toxicities included fatigue (G1-2 67%),
diarrhoea (G1-2 45%; G3-4 11%), nausea (G1-2 45%),
hypertension (G1-2 45%) and increase in liver enzymes
(G1-2 34%; G3-4 11%). A dose reduction was required in
3/9 (34%) patients. One patient discontinued treatment be-
cause of persistent G3 increase in total bilirubin level, one
due to patient’s choice, seven because of progressive
disease.
Discussion
Here, for the first time, we reported prolonged PFS and
OS in metastatic DCRST patients treated with pazopa-
nib and progressing on previous chemotherapy. The ob-
served PFS 9.2 (95%CI: 0–23.2) is remarkable, especially
if compared with the survival recently reported on suni-
tinib (2.6 months) or temsirolimus (9 months, one pa-
tient only) and with the one in the PALETTE study,
which was 4.6 months only [6,23,27]. The OS in the
present series (15.4 months; 95%CI: 1.5-29.3) appears
also encouraging as compared to the OS in the PAL-
ETTE study (12.5 months) [6].
Previous series showed a survival improvement in
DSRCT patients treated upfront with aggressive multi-
modal approach including the use of a multi-agents
alkylator-based first-line regimen (P-6 regimen), surgical
debulking, and radiotherapy (3-years survival: 55% vs
27% when all three modalities were not used; P < 0.02)
[12,15,28]. However, the use of the P-6 regime is limited
by substantial toxicity. More recently, encouraging results
have been also reported with the use of standard Ewing
sarcoma regimens in the first line (VIDE and VDC/IE),
with a median TTP of approximately 15 months and a
favourable tolerability profile [29,30]. Two cases in litera-
ture suggested the efficacy of trabectedin in DSRCT,
which is considered an option in patients with recurrent
disease [31,32]. Despite the efforts done, the outcome of
DSRCT patients is still miserable: even with a high initial
response rate to alkylator-based regimens (90-95%), the
median time to progression (TTP) on/after the first-line
chemotherapy has been recently reported to be approxi-
mately 4 months, the efficacy and regimen of chemo-
therapy at the time of progression is unproven and the
overall median survival is about 16 to 23 months
Table 1 Pazopanib in advanced desmoplastic small round cell tumour
Case Age at onset
of pazopanib
Sex PS Site of metastases Starting
dose (mg)
Dose
reduction
Best
response
PFS
(months)
OS
(months)
1 21 M 2 Peritoneum, liver, kidney 600 N PD 0.5 2.1
2 22 M 1 Peritoneum 800 Y SD 9.2 9.7
3 47 M 1 Peritoneum, liver 800 N PR 16.3 25.8
4 21 M 1 Peritoneum, liver 800 N SD 3.9 9.2
5 30 M 0 Peritoneum, lung, lymph nodes, liver 800 Y PD 2.5 7.4
6 33 M 0 Peritoneum, liver 800 Y SD 9.4 15.4
7 20 M 1 Peritoneum, lung, bone 800 N SD 4.4 26
8 30 M 0 Peritoneum, liver, lymphnodes 800 N SD 9.9 26.7*
9 30 M 0 Peritoneum, liver 800 N PR 13.1 13.8*
*Still alive.
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[11,30]. Therefore, the identification of different pathways
potentially relevant in the pathogenesis and the develop-
ment of novel compounds potentially active in the treat-
ment of this aggressive disease is crucial. The oncogenic
fusion product EWSR1/WT1 in DSRCT was reported to
activate the IGF-1R gene promoter, providing the basis to
test the activity of anti-IGF-1R antibodies in the metastatic
setting. In a recent phase II study, ganitumab administered
in 16 metastatic DSRCT patients determined one PR (6%)
and 10 (63%) SD, with a median PFS of 15 months [33]. A
different anti-IGF-1R antibody, cixutumumab, has been
recently tested in a phase I study in combination with
temsirolimus, an m-TOR inhibitor which efficacy in
DSRCT has been previously described in a case report
by Thijs A. et al. [27,34].
In our series, all the patients included were males and
most of them (88%) had a good ECOG PS (0–1). The
high percentage of ECOG PS 0–1 in the context of sec-
ond line or beyond highlights the non-occasional dis-
crepancy between symptoms and tumour burden in this
disease. It is indeed remarkable that some patients can
be asymptomatic while having significant tumour load.
Pazopanib was found to be well tolerated and most of
the toxicities recorded were mild and manageable with
medical treatment. One third of the patients (3/9) re-
quired dose reduction. In one case it was needed because
of persistent fatigue: interestingly, fatigue was reported to
occur in 49% of the patients included in the PALETTE
placebo arm, suggesting that it might be partly due to the
disease itself [6]. In one case, the dose was reduced for un-
controlled hypertension, and in the third case because of
persistent G3 increase in liver enzymes, which finally led
to treatment discontinuation. The outcome in this popula-
tion was also encouraging: 78% of the patients reported a
partial response or a disease stabilisation for more than
12 weeks. Interestingly, two patients, 47 and 30 years old,
PS: 1 and 0, both with widespread peritoneal sarcomatosis
and liver metastases, achieved a prolonged response (16.3
and 13.1 months respectively) with a significant shrinkage
of peritoneal disease (Figure 1) associated with symptoms
remission (improve of pain control).
Given the good tolerability profile and the activity
shown in the metastatic setting, pazopanib should be
regarded as a valuable treatment option in DSRCT pa-
tients progressing after first line chemotherapy. Pazopa-
nib administration as a maintenance treatment after
induction, with the aim to prolong disease-free survival,
to improve quality of life through symptoms control and
to delay the need for further chemotherapy could also
represent an attractive option for these patients, whose
life expectancy is likely to be limited by the disease.
We are aware that the value of this study is strongly
limited by the small sample size and its retrospective
character. Further evaluation through a global collabora-
tive, prospective, study in a larger cohort of patients is
mandatory.
Conclusions
This case series shows promising activity of pazopanib
in DSRCT patients progressing after prior chemotherapy
without considerable toxicity. International collaborative
effort is needed to confirm these preliminary findings, to
establish its place in the whole treatment of DSRCT, and
to finally improve the outcome of patients with this in-
curable and miserable disease.
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